Latest News

Autolus Therapeutics aiming for NASDAQ IPO

This April, Autolus Therapeutics and Miltenyi Biotec inked a long-term agreement on the supply and support of Miltenyi Biotec’s CliniMACS Prodigy instruments, reagents and disposables for the manufacture of Autolus’ programmed T cell therapies. © Miltenyi Biotec


by tg

British T cell player, Autolus Therapeutics Ltd. wants to go NASDAQ selling 7.8 million American Depositary Shares (ADSs) at  at least US-$15, totaling in US$117m. Through a greenshoe option, Autolus want to offer additional 1,171,875 ADS at the IPO price. 

Goldman Sachs & Co. LLC and Jefferies LLC are acting as joint book-running managers for the offering. Wells Fargo Securities, LLC and William Blair & Company, L.L.C. are acting as lead managers.

The company is well-financed. Last September, Autolus added a US$80m Series C equity funding to US$96m raised in previous financing rounds led by Syncona Ltd., Woodford Investment Management, and Arix Bioscience plc.

Autolus‘ T cell therapies target the the blood cancer ALL either through CD19 (in Phase I) a similar approach to approved CAR-T cell therapies from Novartis and Gilead Sciences, or through targeting CD19 and CD22 (Phase I/II). The company's CD19 candidate however is claimed "next-generation" due to its fast CD19 dissociation kinetics, which allows to target many CD19+ cells very rapidly. Furthermore, the company’s CAR-T cells target CD269 and TACI to treat multiple myeloma (Phase I/II). An additional candidate undergoing Phase I safety testing targets GD2, a disialoganglioside expressed on tumours of neuroectodermal origin, to treat the rare childhood brain cancer neuroblastoma.

Novel adjuvant teases T cells to respond to HCV

In Science Translational Medicine, the team headed by Ilaria Esposito from the University of Rome reports that their novel virally-administered...

VarmX bags €32m in Series B round

New investors LSP, Ysios Capital, INKEF Capital and Lundbeckfonden Ventures joined the financing round, with the contribution of existing investors...

Hyloris Pharmaceuticals prepared to go public

Reformulation specialist Hyloris Pharmaceuticals SA  wants to go public on the regulated market of Euronext Brussels. The company reformulates...

Cevec launches ELEVECTA platform

At the time of Cevec Pharmaceuticals’s announcement, US researchers reported that AAV gene therapy might be the most promising way to bridge the...

S-Protein: Glycosylation pattern revealed

Using high-resolution mass spectrometry, researchers at the University of Southampton have mapped glycan-processing states of the spike protein...

Immatics launches US$250m Nasdaq-IPO

T cell therapy specialist Immatics N.V.  achieved an initial market capitalisation of US$253m through a mixture of Nasdaq listing and...

First drug found to reduce COVID-19-mortality

According to Principal Investigator Peter Horby from the University of Oxford, the cheap immunomodulatory drug dexamethasone helped reducing...